Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Public ClinicalTrials.gov record NCT01536054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Study identification
- NCT ID
- NCT01536054
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Enrollment
- 7 participants
Conditions and interventions
Conditions
- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer
- Stage IIA Fallopian Tube Cancer
- Stage IIA Ovarian Epithelial Cancer
- Stage IIA Primary Peritoneal Cavity Cancer
- Stage IIB Fallopian Tube Cancer
- Stage IIB Ovarian Epithelial Cancer
- Stage IIB Primary Peritoneal Cavity Cancer
- Stage IIC Fallopian Tube Cancer
- Stage IIC Ovarian Epithelial Cancer
- Stage IIC Primary Peritoneal Cavity Cancer
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Epithelial Cancer
- Stage IIIA Primary Peritoneal Cavity Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Epithelial Cancer
- Stage IIIB Primary Peritoneal Cavity Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Epithelial Cancer
- Stage IIIC Primary Peritoneal Cavity Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Primary Peritoneal Cavity Cancer
Interventions
- ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine Biological
- laboratory biomarker analysis Other
- sargramostim Biological
- sirolimus Drug
Biological · Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 19, 2012
- Primary completion
- Apr 20, 2015
- Completion
- Apr 20, 2015
- Last update posted
- Mar 26, 2020
2012 – 2015
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01536054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2020 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01536054 live on ClinicalTrials.gov.